Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - pertuzumab; trastuzumab - injection, solution - pertuzumab 1200 mg; trastuzumab 600 mg

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - pertuzumab; trastuzumab - injection, solution - pertuzumab 600 mg; trastuzumab 600 mg

Israel - English - Ministry of Health

medison pharma ltd - cytarabine; daunorubicin as hcl - powder for concentrate for solution for infusion - cytarabine 100 mg/vial; daunorubicin as hcl 44 mg/vial - daunorubicin and cytarabine - vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc).

European Union - English - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - breast neoplasms - antineoplastic agents - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

Kenya - English - Pharmacy and Poisons Board

getwell pharmaceuticals ltd 474, udyog vihar, phase-v, gurugram- 122016, - ifosfamide usp and mesna bp - powder for injection - 2gm of sterile ifosfamide usp and mesna bp… - combinations of antineoplastic agents

European Union - English - EMA (European Medicines Agency)

jazz pharmaceuticals ireland limited - daunorubicin hydrochloride, cytarabine - leukemia, myeloid, acute - antineoplastic agents - vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc).

Canada - English - Health Canada

jazz pharmaceuticals ireland limited - daunorubicin; cytarabine - powder - 44mg; 100mg - daunorubicin 44mg; cytarabine 100mg - antineoplastic agents

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - pertuzumab; trastuzumab - solution for injection - trastuzumab 40 mg/ml; pertuzumab 80 mg/ml - pertuzumab and trastuzumab - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy for:•the neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer .•the adjuvant treatment of patients with her2-positive early breast cancer (node positive) at high risk of recurrence.metastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel for the treatment of patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease.

Israel - English - Ministry of Health

roche pharmaceuticals (israel) ltd - pertuzumab; trastuzumab - solution for injection - trastuzumab 60 mg/ml; pertuzumab 60 mg/ml - pertuzumab and trastuzumab - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy for:•the neoadjuvant treatment of patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer .•the adjuvant treatment of patients with her2-positive early breast cancer (node positive) at high risk of recurrence.metastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel for the treatment of patients with her2-positive metastatic breast cancer who have not received prior anti-her2 therapy or chemotherapy for metastatic disease.

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.